1081-73-8

Usage

Uses

1-[2-(4-Bromophenoxy)ethyl]pyrrolidine was used in the synthesis of 4-OCH2CH2 -pyrrolidine.

InChI:InChI=1/C11H7ClF3N/c1-6-5-9(12)7-3-2-4-8(10(7)16-6)11(13,14)15/h2-5H,1H3

Upstream product

• 106-41-2 4-bromo-phenol 
• 7250-67-1 1-(2-chloroethyl)pyrrolidine hydrochloride 
• 123-75-1 pyrrolidine 
• 55162-34-0 1-bromo-4-(2-chloroethoxy)benzene 
• 34743-88-9 2-(4-bromophenoxy)ethanol 

Downstream Products

• 193964-15-7 6-methoxy-2-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]benzo[b]thiophene 
• 193965-31-0 5-methoxy-2-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]benzo[b]thiophene 
• 193965-80-9 4-Methoxy-2-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]benzo[b]thiophene 
• 193964-19-1 2-[4-[2-(1-pyrrolidinyl)ethoxy]-phenyl]benzo[b]thiophene 
• 15917-44-9 (Z)-1,2-diphenyl-1-{4-[2-(N-pyrrolidino)ethoxy]phenyl}-1-butene 
• 179018-80-5 pyridin-4-yl[4-(2-pyrrolidin-1-ylethoxy)phenyl]methanol 
• 179018-79-2 pyridin-3-yl-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-methanol 
• 179018-87-2 furan-2-yl-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-methanol 
• 179018-88-3 furan-3-yl-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-methanol 
• 179018-86-1 [4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-thiophen-3-yl-methanol 
• 193966-76-6 6-benzyloxy-2-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]benzo[b]thiophen-3-yl 3-methoxy-4-[(1-pyrrolidinyl)methyl]phenyl ketone 
• 179018-95-2 (3-chloro-phenyl)-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-methanol 
• 179018-82-7 (2-methoxy-phenyl)-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-methanol 
• 1026840-59-4 cyclohexyl-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-methanol 

Relevant academic research and scientific papers

N2-substituted alkoxy aromatic cyclo-2-aminopyrimidine derivative and application thereof

The invention provides an N2-substituted alkoxy aromatic cyclo-2-aminopyrimidine derivative and application thereof. The N2-substituted alkoxy aromatic cyclo-2-aminopyrimidine derivative comprises anoptical isomer and pharmaceutically acceptable salt thereof. Preliminary pharmacodynamic indication shows that the compound disclosed by the invention has FLT3 inhibitory activity, wherein the proliferation inhibition activity is realized on various leukemia cell strains; moreover, the derivative is effective for multiple mutations of AML, such as internal tandem repeat mutation of a near-membranestructural domain and D835 point mutation of an activated ring in a kinase structural domain and almost has no inhibition effect on c-KIT. The derivative can overcome drug resistance brought by clinical point mutation, can reduce toxic and side effects of bone marrow inhibition, and can be applied to preparation of antitumor drugs. The general structural formula of the derivative is shown in thespecification.

LTA4 Hydrolase inhibitors

The present invention provides compounds of the formula Ar1-Q-Ar2-Y-R-Z and pharmaceutically acceptable salts thereof wherein Ar1 and Ar2 are optionally substituted aryl moieties, Z is an optionally substituted nitrogen-containing moiety which may be an acyclic, cyclic or bicyclic amine or an optionally substituted monocyclic or bicyclic nitrogen-containing heteroaromatic moiety; Q is a linking group capable of linking two aryl groups; R is an alkylene moiety; Y is a linking moiety capable of linking an aryl group to an alkylene moiety and wherein Z is bonded to R through a nitrogen atom. The compounds and pharmaceutical compositions of the present invention are useful in the treatment of inflammatory diseases which are mediated by LTB4 production, such as proriasis, ulcerative colitis, IBD and asthma.

Development of an efficient and stereoselective manufacturing route to idoxifene

A literature route to 1-(2-{4-[(E)-1-(4-iodophenyl)-2-phenyl-but-1-enyl]phenoxy}ethyl)pyrrolidine (idoxifene) has been modified to tackle various scale-up issues and provide initial supplies. A new highly efficient, robust, and stereoselective manufacturing route is described in detail. This route involves diastereoselective synthesis of tertiary alcohol (1RS,2SR)-1-(4-iodophenyl)-2-phenyl-1-[4-(2-pyrrolidin-1-yl-ethoxy)phenyl]butan- 1-ol by Grignard addition to the ketone 1-(4-iodophenyl)-2-phenyl-1-butanone followed by derivatisation and stereoselective syn elimination to provide idoxifene in excellent yield and geometric purity. Evaluation of a more direct route to idoxifene using a McMurry low-valent titanium coupling reaction is also described.

Structure-activity relationship studies on 1-[2-(4- phenylphenoxy)ethyl]pyrrolidine (SC-22716), a potent inhibitor of leukotriene A4 (LTA4) hydrolase

Leukotriene B4 (LTB4) is a pro-inflammatory mediator that has been implicated in the pathogenesis of a number of diseases including inflammatory bowel disease (IBD) and psoriasis. Since the action of LTA4 hydrolase is the rate-limiting step for LTB4 production, this enzyme represents an attractive pharmacological target for the suppression of LTB4 production. From an in- house screening program, SC-22716 (1, 1-[2-(4- phenylphenoxy)ethyl]pyrrolidine) was identified as a potent inhibitor of LTA4 hydrolase. Structure-activity relationship (SAR) studies around this structural class resulted in the identification of a number of novel, potent inhibitors of LTA4 hydrolase, several of which demonstrated good oral activity in a mouse ex vivo whole blood assay.